IMCR
Immunocore Holdings plc
$29.58
-3.40%
2026-05-08
About Immunocore Holdings plc
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Key Fundamentals
Forward P/E
-26.62
EPS (TTM)
$-0.56
ROE
-9.6%
Revenue Growth (YoY)
24.3%
Profit Margin
-8.9%
Debt/Equity
114.61
Price/Book
4.07
Beta
0.74
Market Cap
$1.56B
Avg Volume (10D)
388K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$34.91
60D Low
$27.56
Avg Volume
384K
Latest Close
$29.58
Get breakout alerts for IMCR
Sign up for Breakout Scanner to receive daily notifications when IMCR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Immunocore Holdings plc (IMCR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IMCR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IMCR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.